Jubilant Pharmova Ltd

  • BSE Code : 530019
  • NSE Symbol : JUBLPHARMA
  • ISIN : INE700A01033
  • Industry :PHARMACEUTICALS - INDIAN - BULK DRUGS

up-arrow 946.40 -13.40(-1.40%)

Open Price (₹)

953.30

Prev. Close (₹)

959.80

Volume (No’s)

10,912

Market Cap (₹)

15,289.61

Low Price (₹)

946.40

High Price (₹)

959.80

 

Board Meetings

Start Date End Date Purpose
07-Oct-2026 12-Oct-2026 Inter alia, to consider and approve raising of funds through the issuance of NonConvertible Debentures (NCDs) and/or such other securities as may be permitted under applicable laws, and to approve seeking shareholders' approval, as may be required in this regard. Outcome of the Board meeting held on October 12, 2026 pursuant to the provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations) - Issuance of Secured / Unsecured, Listed, Rated, Redeemable Non-Convertible Debentures (NCDs) on Private Placement Basis - Regulation 30 of the SEBI Listing Regulations (As Per BSE Announcement Dated On : 09.10.2026)
30-Jul-2026 10-Aug-2026 Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2026 inter alia to consider and approve Intimation of Board Meeting scheduled for August 07 2026 Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve the Un-audited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026 (As per BSE Announcement dated on: 05.08.2026) outcome of Board meeting (As Per BSE Announcement Dated on: 10/08/2026)
24-Apr-2026 22-May-2026 Audited Results & Final Dividend Audited Financial Results for the quarter and year ended March 31, 2026 Change in CFO Appointment of MD and JMD (As Per BSE Announcement Dated on:22.05.2026)
22-Jan-2026 06-Feb-2026 Quarterly Results Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2026 ,inter alia, to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company For The Quarter and Nine Months Ended December 31, 2025 . Outcome of Board Meeting held on February 06, 2026 (As per BSE Announcement dated on: 06.02.2026)
14-Oct-2025 31-Oct-2025 Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/10/2025 inter alia to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter and half year ended September 30 2025 Outcome of the Board Meeting held on October 31, 2025 Un-audited Financial Results for the quarter and half year ended September 30, 2025 Approval of Grant of Stock Options/RSUs (As Per BSE Announcement Dated on:31.10.2025)

Copyright © 2026 Arihant Capital Markets Ltd. All rights Reserved.

Designed, Developed and Content powered by CMOTS InfoTech (ISO 9001:2015 & ISO/IEC 27001:2022 Certified)

x
  • QR-CodeNew